06.01.2022 07:00:11
|
Reduced schedule for Baloise CEO Gert De Winter
Baloise Holding AG
/ Key word(s): Miscellaneous
Basel, 6 January 2022. Following a cancer diagnosis, Baloise Group CEO Gert De Winter will be stepping back from his frontline duties, probably until into the summer of 2022, so that he can focus on his treatment. He will continue to oversee strategic matters, in particular the launch of Season 2 of the Simply Safe strategy. Baloise Switzerland CEO Michael Müller will take over the day-to-day running of the business. Group CEO Gert De Winter is giving notice today that a tumour has been discovered in his oesophagus that requires medical treatment. The prognosis for recovery from the pre- and post-operative treatments and surgery is good. Gert De Winter will be working to a reduced schedule, probably until into the summer this year, because of the hospital stay and the time that will be required for treatment and rehabilitation. However, he will continue to have oversight of strategic matters. Baloise Switzerland CEO Michael Müller will take over the day-to-day running of the business in addition to his existing role. This will ensure continuity of ongoing projects, in particular the transition to the new strategic phase 'Simply Safe: Season 2'. 'We are optimistic that Gert will be able to return to a full-time schedule later in the year. The entire Baloise family wishes him a full recovery and an abundance of strength for the treatment ahead,' says Chairman of the Board of Directors Thomas von Planta. Contact The Baloise Group is more than just a traditional insurance company. The changing security, safety and service needs of society in the digital age lie at the heart of its business activities. The approximately 7,700 employees of Baloise therefore focus on the wishes of their customers. The best possible customer service, combined with innovative products and services, makes Baloise the first choice for people who want to feel simply safe. Located at the heart of Europe, with its head office in Basel, the Baloise Group is a provider of prevention, pension, assistance and insurance solutions. Its core markets are Switzerland, Germany, Belgium and Luxembourg. In Switzerland, with Baloise Bank SoBa, the Group also operates as a specialised financial services provider, offering a combination of insurance and banking services. The Group offers innovative pension products to private customers throughout Europe from its competence centre in Luxembourg. The shares of Bâloise Holding Ltd are listed in the main segment of SIX Swiss Exchange.
End of Media Release |
Language: | English |
Company: | Baloise Holding AG |
Aeschengraben 21 | |
4002 Basel | |
Switzerland | |
Phone: | +41 61 285 85 85 |
Fax: | +41 61 285 70 70 |
E-mail: | media.relations@baloise.com |
Internet: | https://www.baloise.com |
ISIN: | CH0012410517 |
Listed: | BX Berne eXchange; SIX Swiss Exchange |
EQS News ID: | 1265308 |
End of News | EQS News Service |
|
1265308 06.01.2022
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Baloise AG (N) (Baloise Holding)mehr Nachrichten
09.12.24 |
SPI-Papier Baloise-Aktie: So viel Gewinn hätte ein Investment in Baloise von vor 3 Jahren eingefahren (finanzen.at) | |
09.12.24 |
Veränderungen im Verwaltungsrat der Baloise Holding AG (EQS Group) | |
09.12.24 |
Changes to the Board of Directors of Baloise Holding Ltd (EQS Group) | |
02.12.24 |
SPI-Titel Baloise-Aktie: So viel hätten Anleger an einem Baloise-Investment von vor einem Jahr verdient (finanzen.at) | |
27.11.24 |
Reisen, Familie und finanzielle Sicherheit: Die Top-Lebensziele der Schweizer Bevölkerung (EQS Group) | |
27.11.24 |
Travel, family and financial security: the top life goals of the Swiss (EQS Group) | |
26.11.24 |
Charles Ischi AG gewinnt den InnoPrix SO! 2024 für zukunftweisendes Pharmaprüfgerät (EQS Group) | |
26.11.24 |
Charles Ischi AG wins the 2024 InnoPrix SO! award for its innovative pharmaceutical tester (EQS Group) |